Skip to main content
Premium Trial:

Request an Annual Quote

Precipio Hematologic Malignancy Test Receives NY State Approval

NEW YORK – Diagnostics company Precipio announced on Thursday that it has received New York state approval for its Hemescreen MPN panel hematologic malignancy test.

The molecular test uses the firm's high resolution melt technology to detect hematologic malignancies. With the state approval, the real-time PCR-based assay for myeloproliferative disorders can now be used by New York-based physician-owned labs as a laboratory-developed test.

Precipio's customer New York Cancer and Blood Specialists (NYCB) validated the test and submitted it to the New York State Department of Health. Precipio noted in a statement that NYCB could potentially generate seven-figure revenues for Precipio.

The New Haven, Connecticut-based company has an anemia panel and an acute myeloid leukemia panel for use with its Hemescreen technology.

Although the state approval was only for its MPN panel, other panels using the tech can be submitted by NYCB as add-ons under the umbrella of the Hemescreen platform, a spokesperson for the company said.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.